Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 21, 2026

Novo Nordisk and Aspect Biosystems advance partnership for diabetes therapies

Novo Nordisk and Aspect Biosystems have commenced a new phase in their ongoing partnership focused on curative cellular medicines to treat diabetes.

Novo Nordisk will make an additional equity investment in Aspect, along with research funding to further the therapies. Credit: Kittyfly / Shutterstock.com.